Pancreatic Cancer Research

ResearcherUniversity of LiverpoolActive in the last 2 years

David Goldstein

Matched on OpenAlex author ID A5113674669. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
60
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 9

  1. Aiming for high quality of care for completed resections and improved margin status in pancreatic cancer surgery. Co-author DOI 10.1016/j.pan.2025.09.029↗
  2. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colo… Last author DOI 10.1136/jitc-2022-006136↗
  3. The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2021.11.005↗
  4. Prognostic models to predict survival in patients with pancreatic cancer: a systematic review. Co-author DOI 10.1016/j.hpb.2022.01.011↗
  5. Biliary Stenting in Patients With Pancreatic Cancer: Results From a Population-Based Cohort Study. Co-author DOI 10.1097/mpa.0000000000000960↗
  6. Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. Last author DOI 10.2147/cmar.s163475↗
  7. Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1097/mpa.0000000000000384↗
  8. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗
  9. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Co-author DOI 10.1056/nejmoa1304369↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rachel Ε. Neale · 5 shared papers, 2015–2025 · strength 0.57
  2. Neil Donald Merrett · 5 shared papers, 2015–2025 · strength 0.57
  3. James G. Kench · 3 shared papers, 2022–2025 · strength 0.45
  4. Ashika D. Maharaj · 3 shared papers, 2022–2025 · strength 0.45
  5. John Raymond Zalcberg · 3 shared papers, 2022–2025 · strength 0.45
  6. Liane Ioannou · 3 shared papers, 2022–2025 · strength 0.45
  7. Charles H. C. Pilgrim · 3 shared papers, 2022–2025 · strength 0.45
  8. Sue Evans · 3 shared papers, 2022–2025 · strength 0.45
  9. Kate White · 3 shared papers, 2022–2025 · strength 0.45
  10. Daniel Gerald Croagh · 3 shared papers, 2022–2025 · strength 0.45
  11. Elizabeth A. Burmeister · 4 shared papers, 2015–2022 · strength 0.36
  12. Jaswinder Singh Samra · 1 shared paper, 2025 · strength 0.20
  13. Koroush Shahsavar Haghighi · 1 shared paper, 2025 · strength 0.20
  14. Nick Pavlakis · 1 shared paper, 2023 · strength 0.16
  15. Andrew Mark Haydon · 1 shared paper, 2023 · strength 0.16
  16. Charlotte Lemech · 1 shared paper, 2023 · strength 0.16
  17. Matthew Burge · 1 shared paper, 2023 · strength 0.16
  18. Elena Gabriela Chiorean · 2 shared papers, 2013–2018 · strength 0.12
  19. Daniel D. Von Hoff · 2 shared papers, 2013–2018 · strength 0.12
  20. Madeleine E. Payne · 2 shared papers, 2015–2018 · strength 0.12
  21. Helen M. Gooden · 2 shared papers, 2015–2018 · strength 0.12
  22. Monika Janda · 2 shared papers, 2015–2018 · strength 0.12
  23. Vanessa L. Beesley · 2 shared papers, 2015–2018 · strength 0.12
  24. Jennifer A. M. Philip · 1 shared paper, 2022 · strength 0.11
  25. Trevor Leong · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.